Medicxi Ventures Launches As Independent Venture Capital Firm

(RTTNews) - Medicxi Ventures, a new venture capital firm comprising all of the existing life sciences portfolio companies, funds and team from Index Ventures, today announces the close of Medicxi Ventures 1 or MV1, a new €210 million or $250 million fund that will focus on early-stage life sciences investments.

Medicxi Ventures 1 will predominantly invest in Europe and principally follow the "asset-centric" strategy pioneered by its partners at Index.

By investing in MV1, GlaxoSmithKline (GSK, GSK.L) and Johnson & Johnson Innovation - JJDC, Inc. have renewed and expanded their commitment to the asset-centric approach, following the prior investment in Index Life 6 (IL-6) alongside other financial investors.

Medicxi Ventures will be managed by four General Partners, Francesco De Rubertis, David Grainger, Kevin Johnson and Michèle Ollier, all of whom previously led the life sciences practice of Index Ventures. The four partners will form the executive management of the new firm.